Vaxcyte Financial Ratios
NASDAQ: PCVXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
71.38+6.37 (+9.79%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vaxcyte ratio analysis
Return on equity reached -28.5%, meaning Vaxcyte generated -0.29 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Vaxcyte financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Price / book | 2.35 | 3.13 | 4.92 | 3.26 | 4.35 | 2.27 | — | — |
| Return on equity (ROE) | -28.5% | -14.0% | -32.4% | -23.4% | -35.2% | -25.8% | — | — |
| Return on assets (ROA) | -25.5% | -13.2% | -28.6% | -22.2% | -30.9% | -22.7% | -76.5% | — |
| Current ratio | 7.91 | 12.75 | 7.54 | 23.26 | 8.93 | 8.30 | 5.58 | — |